(Hedgeweek) Rhenman & Partners Asset Management, a Stockholm-based hedge fund firm which invests in global healthcare stocks, is optimistic about a post-US election market bounce, and points to “intense activity” among vaccine developers working on a treatment for Covid-19. To read this article:
Healthcare hedge fund Rhenman eyes “intense” Covid-19 vaccine activity
This entry was posted in Syndicated. Bookmark the permalink.
